These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26813447)

  • 61. 'Effaced bilateral retromaxillary fat pad sign' in bilateral masseter and temporalis muscle hypertrophy.
    Harsha KJ; Parameswaran K
    Neurol India; 2017; 65(2):410-411. PubMed ID: 28290417
    [No Abstract]   [Full Text] [Related]  

  • 62. Botulinum toxin treatment of bilateral masseteric hypertrophy.
    Smyth AG
    Br J Oral Maxillofac Surg; 1994 Feb; 32(1):29-33. PubMed ID: 8136335
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Simultaneous Bilateral Hypertrophies of the Parotid Gland and Masseter Muscle: Case Report.
    Prabhu R; Mandel L
    J Oral Maxillofac Surg; 2017 Jan; 75(1):149-152. PubMed ID: 27528104
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Management of unilateral idiopathic masseter muscle hypertrophy with botulinum toxin type A.
    Nilesh K; Dharamsi R; Patil P; Mate P
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33462041
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Peculiar presentation of bilateral temporalis muscle hypertrophy--report of a case and review of literature.
    Pasupathy S; Yuvaraj V
    Oral Maxillofac Surg; 2010 Sep; 14(3):183-5. PubMed ID: 20099005
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Discussion on The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy.
    Hwang K
    Dermatol Surg; 2014 Dec; 40(12):1340-1. PubMed ID: 25380090
    [No Abstract]   [Full Text] [Related]  

  • 67. Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy.
    Klein FH; Brenner FM; Sato MS; Robert FM; Helmer KA
    An Bras Dermatol; 2014; 89(6):878-84. PubMed ID: 25387491
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ultrasound-Guided Botulinum Neurotoxin Injection for Masseter Hypertrophy Based on the Structural Pattern of Deep Inferior Tendon and Masseteric Contraction.
    Wang YH; Chang SL; Hu S; Huang YL
    Plast Reconstr Surg; 2022 Jul; 150(1):240e-242e. PubMed ID: 35767638
    [No Abstract]   [Full Text] [Related]  

  • 69. [Noninvasive monitoring of changes in the structure and function of masseter muscles after the injection of botulinum toxin type A].
    Guo Z; Diao X; Xia W; Liu T; Chen Y; Zheng J; Zhou Z; Yang P; Zhu J
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2016 Nov; 32(6):437-40. PubMed ID: 30067323
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study.
    Sidebottom AJ; Patel AA; Amin J
    Br J Oral Maxillofac Surg; 2013 Apr; 51(3):199-205. PubMed ID: 22871559
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique.
    Guarda-Nardini L; Stecco A; Stecco C; Masiero S; Manfredini D
    Cranio; 2012 Apr; 30(2):95-102. PubMed ID: 22606852
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Quantitative analysis based on three-dimensional stereophotogrammetry in the observation of curative effect of botulinum toxin A on masseter hypertrophy].
    Xue Z; Zeng W; Chen Z; Han Y
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2016 Jul; 32(4):272-5. PubMed ID: 30044570
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Masseter and medial pterygoid muscle hypertrophy.
    Guruprasad R; Rishi S; Nair PP; Thomas S
    BMJ Case Rep; 2011 Sep; 2011():. PubMed ID: 22679271
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Unilateral temporalis muscle hypertrophy managed with botulinum toxin type A.
    Isaac AM
    Br J Oral Maxillofac Surg; 2000 Oct; 38(5):571-2. PubMed ID: 11010798
    [No Abstract]   [Full Text] [Related]  

  • 75. Botox facial slimming/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width.
    Wu WT
    Facial Plast Surg Clin North Am; 2010 Feb; 18(1):133-40. PubMed ID: 20206096
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The medical management of masseteric hypertrophy with botulinum toxin type A.
    Moore AP; Wood GD
    Br J Oral Maxillofac Surg; 1994 Feb; 32(1):26-8. PubMed ID: 8136334
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy.
    Bae JH; Choi DY; Lee JG; Seo KK; Tansatit T; Kim HJ
    Dermatol Surg; 2014 Dec; 40(12):1334-9. PubMed ID: 25393348
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Botulinum toxin type A treatment of cosmetically disturbing masseteric hypertrophy].
    Rijsdijk BA; van ES RJ; Zonneveld FW; Steenks MH; Koole R
    Ned Tijdschr Geneeskd; 1998 Mar; 142(10):529-32. PubMed ID: 9623101
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison between Conventional Blind Injections and Ultrasound-Guided Injections of Botulinum Toxin Type A into the Masseter: A Clinical Trial.
    Bae H; Kim J; Seo KK; Hu KS; Kim ST; Kim HJ
    Toxins (Basel); 2020 Sep; 12(9):. PubMed ID: 32932891
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of botulinum toxin therapy in treatment of myofascial pain.
    Chaurand J; Pacheco-Ruíz L; Orozco-Saldívar H; López-Valdés J
    J Oral Sci; 2017; 59(3):351-356. PubMed ID: 28904310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.